These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 1963594

  • 1. Substituted thieno[3,4-d]imidazoles, a novel group of H+/K(+)-ATPase inhibitors. Differentiation of their inhibition characteristics from those of omeprazole.
    Beil W, Staar U, Sewing KF.
    Eur J Pharmacol; 1990 Oct 23; 187(3):455-67. PubMed ID: 1963594
    [Abstract] [Full Text] [Related]

  • 2. The inhibitory effect of HOE 731 in isolated rabbit gastric glands.
    Herling AW, Becht M, Lang HJ, Scheunemann KH, Weidmann K, Scholl T, Rippel R.
    Biochem Pharmacol; 1990 Oct 15; 40(8):1809-14. PubMed ID: 2173590
    [Abstract] [Full Text] [Related]

  • 3. By 1023/SK&F 96022: biochemistry of a novel (H+ + K+)-ATPase inhibitor.
    Simon WA, Keeling DJ, Laing SM, Fallowfield C, Taylor AG.
    Biochem Pharmacol; 1990 Jun 01; 39(11):1799-806. PubMed ID: 2160820
    [Abstract] [Full Text] [Related]

  • 4. Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases.
    Mattsson JP, Väänänen K, Wallmark B, Lorentzon P.
    Biochim Biophys Acta; 1991 Jun 18; 1065(2):261-8. PubMed ID: 1647821
    [Abstract] [Full Text] [Related]

  • 5. Omeprazole, SCH 28080 and doxepin differ in their characteristics to inhibit H+/K+-ATPase driven proton accumulation by parietal cell membrane vesicles.
    Beil W, Staar U, Schünemann P, Sewing KF.
    Biochem Pharmacol; 1988 Dec 01; 37(23):4487-93. PubMed ID: 2849447
    [Abstract] [Full Text] [Related]

  • 6. Pantoprazole: a novel H+/K(+)-ATPase inhibitor with an improved pH stability.
    Beil W, Staar U, Sewing KF.
    Eur J Pharmacol; 1992 Aug 06; 218(2-3):265-71. PubMed ID: 1330598
    [Abstract] [Full Text] [Related]

  • 7. Sulfide and sulfoxide derivatives of substituted benzimidazoles inhibit acid formation in isolated gastric glands by different mechanisms.
    Fryklund J, Wallmark B.
    J Pharmacol Exp Ther; 1986 Jan 06; 236(1):248-53. PubMed ID: 3001289
    [Abstract] [Full Text] [Related]

  • 8. The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor.
    Morii M, Takata H, Fujisaki H, Takeguchi N.
    Biochem Pharmacol; 1990 Feb 15; 39(4):661-7. PubMed ID: 2154989
    [Abstract] [Full Text] [Related]

  • 9. A substituted thieno[3.4-d]imidazole versus substituted benzimidazoles as H+, K+-ATPase inhibitors.
    Herling AW, Bickel M, Lang HJ, Weidmann K, Rösner M, Metzger H, Rippel R, Nimmesgern H, Scheunemann KH.
    Pharmacology; 1988 Feb 15; 36(5):289-97. PubMed ID: 2841691
    [Abstract] [Full Text] [Related]

  • 10. Studies on the mechanism of action of the gastric microsomal (H+ + K+)-ATPase inhibitors SCH 32651 and SCH 28080.
    Scott CK, Sundell E, Castrovilly L.
    Biochem Pharmacol; 1987 Jan 01; 36(1):97-104. PubMed ID: 3026407
    [Abstract] [Full Text] [Related]

  • 11. Coupling of H(+)-K(+)-ATPase activity and glucose oxidation in gastric glands.
    Fryklund J, Gedda K, Scott D, Sachs G, Wallmark B.
    Am J Physiol; 1990 May 01; 258(5 Pt 1):G719-27. PubMed ID: 2159239
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of H+,K+-ATPase by methyl(E)-2-(3,4-dimethoxystyryl)-benzimidazole-4-carboxylate (ALE-36).
    Yamamoto O, Tanaka H, Ueda F, Kimura K.
    Scand J Gastroenterol Suppl; 1989 May 01; 162():178-81. PubMed ID: 2556788
    [Abstract] [Full Text] [Related]

  • 13. Evidence for acid-induced transformation of omeprazole into an active inhibitor of (H+ + K+)-ATPase within the parietal cell.
    Wallmark B, Brändström A, Larsson H.
    Biochim Biophys Acta; 1984 Dec 19; 778(3):549-58. PubMed ID: 6095911
    [Abstract] [Full Text] [Related]

  • 14. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione.
    Fujisaki H, Shibata H, Oketani K, Murakami M, Fujimoto M, Wakabayashi T, Yamatsu I, Yamaguchi M, Sakai H, Takeguchi N.
    Biochem Pharmacol; 1991 Jul 05; 42(2):321-8. PubMed ID: 1650210
    [Abstract] [Full Text] [Related]

  • 15. Inhibitory action of omeprazole on acid formation in gastric glands and on H+,K+-ATPase isolated from human gastric mucosa.
    Elander B, Fellenius E, Leth R, Olbe L, Wallmark B.
    Scand J Gastroenterol; 1986 Apr 05; 21(3):268-72. PubMed ID: 3012768
    [Abstract] [Full Text] [Related]

  • 16. The specificity of omeprazole as an (H+ + K+)-ATPase inhibitor depends upon the means of its activation.
    Keeling DJ, Fallowfield C, Underwood AH.
    Biochem Pharmacol; 1987 Feb 01; 36(3):339-44. PubMed ID: 3028428
    [Abstract] [Full Text] [Related]

  • 17. Reversible inhibition of rat gastric H+/K+-ATPase by T-330, 2-[2-dimethylaminobenzyl)sulfinyl]-1-(3-methylpyridine-2-yl)imidazole.
    Kinoshita M, Saito N, Noto T, Tamaki H.
    J Pharmacol Exp Ther; 1996 Apr 01; 277(1):28-33. PubMed ID: 8613931
    [Abstract] [Full Text] [Related]

  • 18. Studies on the mechanism of action of omeprazole.
    Keeling DJ, Fallowfield C, Milliner KJ, Tingley SK, Ife RJ, Underwood AH.
    Biochem Pharmacol; 1985 Aug 15; 34(16):2967-73. PubMed ID: 2992525
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of (H+ + K+)-ATPase and H+ accumulation in hog gastric membranes by trifluoperazine, verapamil and 8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate.
    Im WB, Blakeman DP, Mendlein J, Sachs G.
    Biochim Biophys Acta; 1984 Feb 29; 770(1):65-72. PubMed ID: 6320882
    [Abstract] [Full Text] [Related]

  • 20. Studies on the mechanism of action of the omeprazole-derived cyclic sulphenamide.
    Beil W, Staar U, Sewing KF.
    Biochem Pharmacol; 1988 Mar 01; 37(5):843-8. PubMed ID: 2830883
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.